As targeting FGFR4 becomes increasingly more feasible than directly targeting FGF19, highly selective FGFR4 inhibitors have become commercially available for preclinical tests [46–49], providing new approaches to treat a subgroup of FGF19-driven cancers. Here, FGFR4 is linked to cancer.